Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3399-3406

  Kuriyama, Shigeki ^a   Masui, Kazuhiro ^a   Sakamoto, Takemi ^a   Nakatani, Toshiya ^a   Kikukawa, Masaji ^a   Tsujinoue, Hirohisa ^a   Mitoro, Akira ^a   Yamazaki, Masaharu ^a   Yoshiji, Hitoshi ^a   Fukui, Hiroshi ^a   Ikenaka, Kazuhiro ^b   Mullen, Craig A ^c   Tsujii, Tadasu ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

5 fluorocytosine; 5 fluorouracil; Bystander effect; Cancer; Cytosine deaminase; Gene therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CULTURE MEDIA, CONDITIONED; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; MICE; NUCLEOSIDE DEAMINASES; PRODRUGS; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031788385     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mullen CA: Metabolic suicide genes in gene therapy. Pharmacol Ther 63: 199-207, 1994.
2. Moolten FL: Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287, 1994.
3. Danielsen S, Kilstrup M, Barilla K, Jochimsen B and Neuhard J: Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Mol Microbiol 6: 1335-1344, 1992.
4. Austin E and Huber B: A first step in the development gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993.
5. Mullen CA, Kilstrup M and Blaese M: Transfer of the bacterial gene for cytokine deaminase to mammalian cells confers lethal sensitivity to 5- fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
6. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S and Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619-4626, 1993.
7. Mullen CA, Coale MM, Lowe R and Blaese RM: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503-1506, 1994.
8. Huber BE, Austin EA, Richards CA, Davis ST and Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994.
9. Kuriyama S, Masui K, Sakamoto T, Nakatani T, Tominaga K, Fukui H, Ikenaka K, Mullen CA and Tsujii T: Cytosine deaminase suicide gene transduction renders hepatocellular carcinoma sensitive to the prodrug 5-fluorocytosine. Int Hepatol Commun 4: 72-79, 1995.
10. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ and Crystal RG: k1 vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6: 1055-1063, 1995.
11. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M and Forni G: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 154: 5302-5312, 1995.
12. Richards CA, Austin EA and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995.
13. Ohwada A, Hirschowitz EA and Crystal RG: Regional delivery of an adenovirus vector containing the Echerichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 7: 1567-1576, 1996.
14. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz EA, Crystal R, Weichselbaum R, Kufe DW and Fine HA: In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 7: 713-720, 1996.
15. Rowley S, Lindauer M, Gebert JF, Haberkorn U, Oberdorfer F, Moebius U, Herfarth C and Schackert H-K: Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer. J Surg Oncol 61: 42-48, 1996.
16. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T and Omata M: In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 57: 461-465, 1997.
17. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
18. Cao G, Kuriyama S, Du P, Sakamoto T, Yang W, Masui K and Qi Z: Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. J Gastroenterol Hepatol 11: 1053-1061, 1996.
19. Senter PD, Su P, Katsuragi T, Sakai T, Cosand WL, Hellstrom I and Hellstrom KE: Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem 2: 447-451, 1991.
20. Masuike T, Watanabe I and Takemoto Y: Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography. Yakugaku Zasshi 105: 1058-1064, 1985.
21. Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K and Tsujii T: Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 22: 1838-1846, 1995.
22. Calabrisi P and Chabner BA: Antimetabolites. In: Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. (Gilman AG, Rall TW, Nies AS and Taylor P, eds). New York, Pergamon, 1990, pp 1209-1263.
23. Peterson D, Demertzis S, Freund M, Schumann G and Oellerich M: Individualization of 5-fluorocytosine therapy. Chemotherapy 40: 149-156, 1994.
24. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, Mcgee ZA, Cate TR, Cobbs CG, Warner JF and Ailing DW: A comparison of amphotericine B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New Eng J Med 301: 126-131, 1979.
25. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield E and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
26. Bi WL, Parysek LM, Warnick R and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther 4: 725-731, 1993.
27. Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin D, Ram Z, Oldfield EH, Johns DG and Blaese RM: Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 4: 244-251, 1997.
28. Prisbe EJ, Martin JC, Mcgee DPC, Barker MF, Smee DF, Duke AE, Matthews TR and Verheyden JPH: Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2- propoxy) methyl] guanine. J Med Chem 29: 671-675, 1986.
29. Freeman SM, Abbound CN, Whartenby K, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
30. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V and Spray DC: The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 4: 577-585, 1997.
31. Rogers RP, Ge J-Q, Holley-Guthrie E, Hoganson DK, Comstock KE, Olsen JC and Kenney S: Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum. Gene Ther 7: 2235-2245, 1996.
32. Hoganson DK, Batra RK, Olsen J and Boucher RC: Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res 56: 1315-1323, 1996.
33. Ram Z, Culver KW, Walbridge S, Blaese RM and Oldfield EH: In Situ retroviral-mediated gene transfer for the treatment of brain tumors. Cancer Res 53: 83-88, 1993.